Emcure Pharma Q1 results: Profit jumps 42% YoY to ₹294 crore, revenue climbs 23%; check key numbers

Emcure Pharmaceuticals posted its April to June quarter results for the financial year 2026-27, where the firm recorded a 42% rise in its consolidated net profits, with key support from revenue gains and improving margins in the period.

NSE filings showed that Emcure Pharma posted a 42% year-on-year (YoY) rise in its consolidated net profit to ₹294 crore in the first quarter of the fiscal year 2026-27, in comparison to ₹207 crore in the same period a year earlier.

On a sequential basis, the company’s net profits rose 21% to its June quarter level, from ₹243 crore in the same period a year ago.

The pharma company’s revenue from core operations advanced 23% YoY to ₹2,580 crore in the June quarter, compared with ₹2,101 crore in the same period a year earlier, as per the exchange filing.

Shares of Emcure Pharma declined 2.3% to their intraday low of ₹1,912.90 apiece on Thursday’s market, compared to ₹1,959 apiece in the previous stock market close, NSE data showed.

Margin growth

NSE filings also showed that Emcure Pharma’s operational-level earnings before interest, tax, depreciation, and amortisation (EBITDA) increased 28% YoY to ₹532 crore in the first quarter of the fiscal year 2026-27, compared to ₹417 crore in the same period a year earlier.

On the margins front, the pharma company’s EBITDA margins expanded by 79 basis points to 20.63% in the June quarter of FY27, in comparison to 19.84% in the same period last year, according to the exchange filing.

Emcure Pharma shares 52-week high

Shares of Emcure Pharma surged to their 52-week high of ₹2,009.20 on August 5, 2026, while the 52-week low was at ₹1,260 on October 1, 2025, according to the exchange data.

Emcure Pharma shares have delivered more than 34% returns on their investment in the last one year period, and have gained 36% on a year-to-date (YTD) basis in the current year, according to NSE data.

The company’s stock has gained 4.4% in the last one-month period, and has risen 0.2% in the last five market sessions on the stock exchange.

Emcure Pharma’s market capitalisation (m-cap) was at ₹36,570 crore as of the trading session on Thursday, August 6, 2026.